Please login to the form below

Not currently logged in
Email:
Password:

Merck

This page shows the latest Merck news and features for those working in and with pharma, biotech and healthcare.

Innovent gears up for PD-1 inhibitor launch in China

Innovent gears up for PD-1 inhibitor launch in China

The home-grown PD-1 inhibitors join Bristol-Myers Squibb and Merck &Co/MSD’s rival drugs on the Chinese market. ... BMS’ Opdivo (nivolumab) was cleared in China for previously-treated non-small cell lung cancer (NSCLC) in June 2018, while Merck’s

Latest news

More from news
Approximately 346 fully matching, plus 1,236 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    However the last data read-out showed this hit its progression-free survival (PFS) endpoint but not OS – handing a clear advantage to Merck &Co. ... April. Naturally Merck &Co isn’t confining itself to dominance in lung cancer.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    9. Vitrakvi – a novel addition to the immune-oncology market. Earlier this year Merck &Co/MSD became the first company to secure approval for a ‘tissue agnostic’ drug when its ... Merck/MSD looks to have gained a dominant position in checkpoint

  • Is China ready for a pharmaceutical gold rush?

    Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    EvaluatePharma forecasts that Lynparza (now co-marketed with Merck &Co) will hit annual revenues of $2.2bn by 2024, with Imfinzi expected to reach $3.65bn and Tagrisso leading the way ... This gives it a unique niche in an IO lung cancer market dominated

More from intelligence
Approximately 8 fully matching, plus 125 partially matching documents found.

Latest appointments

More from appointments
Approximately 37 fully matching, plus 136 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 33 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics